Solitary Cerebral Cysticercus Granuloma by Nandhagopal, Ramachandiran
A 7-year-old boy from South India presented with recurrent left motor seizure with secondary generalisation. 
The computed tomography scan of his brain 
[Figure 1] demonstrated a solitary enhancing cystic 
lesion with eccentric mural nodule (scolex) in the 
right frontal region. Based on the epidemiological 
profile (he came from an endemic area), as well 
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INTERESTING MEDICAL IMAGE
Figure 1:  Cranial computerised tomography scan demonstrating a single solitary enhancing right frontal cystic lesion 
(arrow) with eccentric mural nodule-scolex (asterix in the inset) and perilesional oedema. 
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as the clinical and imaging findings,1 a diagnosis 
of solitary cerebral cysticercus granuloma was 
made. He was treated with a short course of anti-
cysticercal treatment (albendazole), prednisolone 
(after excluding spinal and ocular cysticercosis) and 
phenytoin. Follow-up imaging at 6 months revealed 
significant improvement. 
Solitary cysticercal cysts are an important cause 
of symptomatic seizure in endemic areas. Other 
clinical manifestations include headache and focal 
neurological deficits. In the natural history of 
neurocysticercosis, the following stages of evolution 
of parenchymal larval cysts can be observed 
on neuroimaging: viable cyst, granulomatous 
cysticercosis and disappearance of cyst with or 
without residual calcification.2 In the viable cyst 
stage, the cyst wall is not visible on imaging and the 
cyst demonstrates little or no perilesional oedema. 
Ring-like or nodular areas of enhancement with 
prominent perilesional oedema mark the phase of 
granulomatous cysticercosis. 
The image shown here demonstrates the 
granulomatous cysticercosis as a ring-enhancing 
lesion with scolex and peri-lesional oedema. 
Ultimately, the remnant of the cyst is either not 
visible on the imaging or observed as calcified 
lesion(s). 
Medical treatment for viable or granulomatous 
cysticercosis includes antihelminthic medication, 
standard anticonvulsants for seizures and 
symptomatic medication such as anti- 
inflammatory drugs such as steroids. Antiparasitic 
therapy for solitary cysticercus granuloma is 
shrouded in controversy for the following reasons: 
1) solitary cysticercus granuloma may resolve 
spontaneously without antihelminthic treatment; 
2) the parasite cannot grow and develop further 
in the cerebral parenchymal location, and 3) 
antihelminthic treatment kills the parasite that 
can potentially cause neurological complications 
such as a transient increase in seizure frequency, 
headaches, and raised intracranial pressure. 
The latter complication is observed especially in 
patients with multiple cysticercus granulomata. 
The arguments for cysticidal therapy include rapid 
disappearance of cyst(s) and the possibility of 
less residual calcification.2 Albendazole in a dose 
of 15 mg/kg/day divided into two doses is the 
antihelminthic drug widely employed. The duration 
of treatment was 1 month in older studies,3 but 
this has been reduced to 15 days and even 1 week 
in later studies.4,5 It is usually administered along 
with corticosteroids to prevent the neurological 
complications associated with the degeneration 
and death of the parasite as mentioned above. A 
recent Cochrane Database systematic review found 
evidence for a reduction both in the number of 
viable lesions and in seizure frequency in those 
patients with non-viable cysts on albendazole 
therapy.6 The other available antihelminthic drug 
is praziquantel, usually given in dose of 50 mg/kg/
day for 2 weeks. A single day course of praziquantel 
has also been employed.7 Surgery is usually 
reserved for extraparenchymal neurocysticercosis 
such as an intraventricular cyst, spinal cysticercosis 
causing spinal cord compression, for hydrocephalus, 
or for ophthalmic cysticercosis.8 
In general, the seizure outcome in solitary 
cerebral cysticercosis is good in view of the 
symptomatic nature of the seizure. The optimal 
duration of anticonvulsant prophylaxis has not been 
finally decided. Some authors favour anticonvulsant 
prophylaxis for 6 months and repeat the 
neuroimaging scan (by CT or magnetic resonance 
imaging) to look for resolution of the lesion with a 
view to tapering anticonvulsants in patients who are 
fit free,8 while others have continued anticonvulsant 
therapy for 2 years.9 Patients with residual 
calcification may be at risk of recurrent seizures. 
The image is mainly presented here to highlight 
the characteristic appearance of cysticercus lesion 
termed 'hole with a dot’;1 the hole represents the 
cysticercus ring lesion itself and the dot the scolex. 
For physicians in non-endemic regions such as 
Oman, awareness of this imaging characteristic 
aids in the recognition of cerebral cysticercosis in 
patients who originate from or have travelled to 
endemic areas.
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